Drug Dosing in Obese Patients: A Dilemma
Prevalence of obesity has increased over the past few years and is still growing. Usually obesity is accompanied by co-morbid conditions which may be caused because of it too. Due to this it is not unusual for a physician to have a lot of obese patients. Now, the dosing of the drug is a major issue. The dose given for normal patients may not be accurate for obese patients and it is highly likely to worsen the condition of the patient on account of the fact that pharmacokinetic parameters of an obese individual differs from a normal person. During clinical trials, the dose is calculated for normal weight patients, but the scenario changes in obese. Due to the lack of sufficient evidence, the dose modification poses to be a threat to patients especially the ones who are on drugs with a narrow therapeutic index. Various scales have been formulated to help but more research needs to be done to get precise doses.
Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes 2008; 32: 1431-37
Yach D, Stuckler D, BrownellKD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006; 12: 62-6
World Health Organization. Obesity and overweight [fact sheet no. 311; online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs311/en/index.html
.Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-209
World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation [WHO technical report no. 894; Online]. Available from URL: http://whqlibdoc.who.int/trs/WHO_TRS_ 894.pdf
Abernethy DR, Greenblatt DJ. Drug disposition in obese humans: an update. Clin Pharmacokinet 1986; 11: 199-213
Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999;88:1-7
Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-31
Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 1982; 7: 108-24
Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet 1993; 25: 103-14
Lee JB, Winstead PS, Cook AM. Pharmacokinetic alterations in obesity. Orthopedics. 2006; 29:984988. [PubMed]
Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med. 2004; 30:1831. [PubMed]
Clin Buckley FP. Anaesthesia for the morbidly obese patient. Can J Anaesth 1994; 41: R94R100
Ijaz S, Yang W, Winslet MC, et al. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003; 10: 447-56
Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82: 505-8
Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000; 38: 415-26
Semchuk WM, Sc M. Medication dosing guidelines in obese adults. RQHR Pharmacy Services. 2007.
Phringer FK, Keller C, Kleinsasser A, et al. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 1999; 16:50710.
Blouin RA, Mann HJ, Griffen WO Jr, et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979; 26:50812.
Bauer LA, Blouin RA, Griffen WO Jr, et al. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 1980; 37:51922.
Adams JP & Murphy PG. Obesity in anaesthesia and intensive care. British Journal of Anaesthesia 2000; 85: 91108
Jaber LA, Antal EJ, Slaughter RL, Welshman IR. The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. European journal of clinical pharmacology. 1993 Dec 1;45(5):459-63.
Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic pharmacodynamic models. Clin Pharmacokinet 1981; 6:42953.
Akinnusi ME, Pineda LA, El Sohl AA. Effect of obesity on critical care morbidity and mortality: a meta?analysis. Critical Care Medicine, 2008; 36: p151?158
Alvarez A, Brodsky J, Lemmens HJ et al. Morbid obesity: perioperative management. 2nd ed. Cambridge University Press, 2010
Michael J. Hanley, Darrell R. Abernethy and David J. Greenblatt Effect of Obesity on the Pharmacokinetics of Drugs in Humans Clin Pharmacokinet 2010; 49 (2): 71-870312-5963/10/0002-0071
Mosteller RD. Simplified calculation of body-surface area.NEngl J Med 1987; 317: 1098
Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008; 4: 108-13
Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. British journal of anaesthesia. 2010 Dec 1;105(suppl 1):i16-23.
Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 105165
Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650-5
Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004; 43: 1167-78
Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119-33.
Kirby. Anaesthesia 1987; 42:11251126
Ingrande. Anesth Analg 2011; 113:5762
Servin. Anesthesiology 1993; 78:657665
Albertin. Br J Anaesth 2007; 98:6675
Buckley FP. Anaesthesia for the morbidly obese patient. Can J Anaesth 1994; 41: R94R100
Jung D, Mayersohn M, Perrier D, Calkins J, Saunders R. Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology. 1982 Apr;56(4):269-74.
Greenblatt DJ, Ehrenberg BL, Gunderman J, Locniskar A, Scavone JM, Harmatz JS, Shader RI. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clinical Pharmacology & Therapeutics. 1989 Apr 1;45(4):356-65.
Reves JG , Fragen RJ, Vinik R, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology, 1985; 62: 310324
Weinstein JA, Matteo RS, Ornstein E, Schwartz AE, Goldstoff M, Thal G. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. Anesthesia & Analgesia. 1988 Dec 1;67(12):1149-53.
Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Pedersen HS. Anthropometric variables as predictors for duration of action of atracurium-induced neuromuscular block. Anesthesia & Analgesia. 1996 Nov 1;83(5):1076-80.
Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesthesia & Analgesia. 2004 Oct 1;99(4):1086-9
Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesthesia & Analgesia. 2004 Oct 1;99(4):1086-9.
Bentley JB, Borel JD, Vaughan RW, Gandolfi AJ. Weight, Pseudocholinesterase Activity, and Succinylcholine Requirement. Survey of Anesthesiology. 1983 Jun 1;27(3):142.
Kirkegaard-Nielsen H, Lindholm P, Petersen HS, Severinsen IK. Antagonism of atracurium-induced block in obese patients. Canadian journal of anaesthesia. 1998 Jan 1;45(1):39-41.
Van Lancker P, Dillemans B, Bogaert T, Mulier JP, De Kock M, Haspeslagh M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia. 2011 Aug 1;66(8):721-5.
Bentley. Anesth Analg 1983; 62:245262
Salihoglu Z, Demiroluk S, Demirkiran O, Kose Y. Comparison of effects of remifentanil, alfentanil and fentanyl on cardiovascular responses to tracheal intubation in morbidly obese patients. European journal of anaesthesiology. 2002 Feb 1;19(02):125-8.
Maitre PO, Vozeh S, Heykants J, Thomson DA, Stanski DR. Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology. 1987 Jan;66(1):3-12.
Bentley JB, Vaughan RW, Cork RC, Gandolfi AJ. Does Evidence of Reductive Halothane Biotransformation Correlate Halothane with Hepatic Binding of Metabolites in Obese Patients?. Anesthesia & Analgesia. 1981 Aug 1;60(8):548-51.
Schwartz AE, Matteo RS, Ornstein E, Young WL, Myers KJ. Pharmacokinetics of sufentanil in obese patients. Anesthesia & Analgesia. 1991 Dec 1;73(6):790-3.
Slepchenko G, Simon N, Goubaux B, Levron JC, Le Moing JP, Raucoules-Aim M. Performance of target-controlled sufentanil infusion in obese patients. The Journal of the American Society of Anesthesiologists. 2003 Jan 1;98(1):65-73.
Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, Muir KT. Remifentanil pharmacokinetics in obese versus lean patients. The Journal of the American Society of Anesthesiologists. 1998 Sep 1;89(3):562-73.
La Colla L, Albertin A, La Colla G, Porta A, Aldegheri G, Di Candia D, et al. Predictive performance of the Mintoremifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clinical pharmacokinetics 2010 Feb;49(2):131-9.
Choi YK, Brolin RE, Wagner BK, Chou S, Etesham S, Pollak P. Efficacy and safety of patient-controlled analgesia for morbidly obese patients following gastric bypass surgery. Obesity Surgery. 2000 Apr 6;10(2):154-9.
Lee WH, KRAMER WG, GRANVILLE GE. The effect of obesity on acetaminophen pharmacokinetics in man. The Journal of Clinical Pharmacology. 1981 Jul 1;21(7):284-7.
DIC/KAUH drug dosing in obesity
Garcia-Saiz M, Lopez-Gil A, Alfonso I, Boada JN, Armijo JA. Factors influencing cyclosporine blood concentration-dose ratio. Ann Pharmacother 2002; 36:193-199.
Dvorchick BH, Damphousse D. The pharmacokinetics of Daptomycin in moderately obese, morbidly obese and matched non obese subjects. Journal of Clinical Pharmacology, 2005; 45:48-56
.Cohen LG, Dibiasio A, Lisco SJ . Hurford WE . Fluconazole serum concentrations and pharmacokinetics in an obese patients. Pharmacother 1997; 17:1023-1026
Ellison MJ, et al. Calculation of heparin dosage in morbidly obese woman. Clin Pharmacokinet 1989; 8:65-68.
Spruill WJ, Wade WE, Huckaby WG, Leslie RB. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health-Sys Pharm 2001;58:2143-2146.
Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity. Determination of loading dose. Arch neurol 1985; 42(5): 468-471
Wilkes L, et al. Phenobarbital pharmacokinetics in obesity. A case report. Clin Pharmacokinet 1992; 22:4814
Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacotherap 2002; 26:1512-1517
Geiseler PJ et al Am Rev Respir Dis 1985; 131(6): 944-6
Jansen B Thursky K Dosing of Antibiotics in Obesity; Current Opinion in Infectious Diseases; 2012; 25(6) p634
Kendrick JG, Carr RR, Ensom MH. Pharmacokinetics and drug dosing in obese children. The Journal of Pediatric Pharmacology and Therapeutics 2010 Apr;15(2):94-109.
Mulla H, Johnson TN. Dosing dilemmas in obese children. Archives of disease in childhood-Education & practice edition. 2010 Aug 1;95(4):112-7.
Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. Br J Anaesth 2005; 95: 37783
Brunette DD. Resuscitation of the morbidly obese patient. The American journal of emergency medicine. 2004 Jan 31;22(1):40-7.
Richard AA et al. Comparison of Anti-Xa Levels in Obese and Non-Obese Pediatric Patients Receiving Treatment Doses of Enoxaparin. J Pediatr 2013; 162:293-6
Taylor BN, Bork SJ, Kim S, Moffett BS, Yee DL. Evaluation of weight-based dosing of unfractionated heparin in obese children. The Journal of pediatrics. 2013 Jul 31;163(1):150-3.
Hurewitz AN, Khan SU, Groth ML, Patrick PA, Brand DA. Dosing of unfractionated heparin in obese patients with venous thromboembolism. Journal of general internal medicine. 2011 May 1;26(5):487-91.
Janson B and Thursky K. Dosing of Antibiotics in Obesity. Current Opinion Infectious Disease 2012; 25: 634-649
Department of Health. Clinical Guidelines for immunoglobulin use. Second edition update, edited for Scotland. March 2013
Flagyl (Metronidazole) Zentiva. Summary of Product Characteristics Accessed at www.medicines.org.uk 17th July 2013
Rice L, Hursting MJ, Baillie GM. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol 2007; 47: 1028-34
Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999; 93: 4436-40
Sauer M, Rydholm N, Piatkowski J, et al. Nephrotoxicity due to intermediate-dose methotrexate without rescue in an obese adolescent with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2002; 19:135140.
De Jonge ME, Matho t RA, van Dam SM, et al. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa, and carboplatin. Cancer Chemother Pharmacol 2002; 50: 251-255.
Copyright (c) 2017 International Journal of Advances in Pharmaceutics
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).